Chart-Typ:
Zeitraum:
| Sonoma Pharmaceuticals, Inc.: National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced | BOULDER, CO / ACCESS Newswire / November 13, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous... ► Artikel lesen |
| Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals to Exhibit at MEDICA 2025 in Düsseldorf | BOULDER, CO / ACCESS Newswire / November 6, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous... ► Artikel lesen |
| Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2026 Financial Results | Revenues increased 57% for the quarter and 38% for the six months ended September 30, 2025 compared to same periods last yearU.S. revenue increased 115% for the quarter and 86% for the six months ended... ► Artikel lesen |
| Jaguar Health, Inc.: Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts | SAN FRANCISCO, CA / ACCESS Newswire / January 14, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday... ► Artikel lesen |
| Jaguar Health, Inc.: Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million | $18M upfront payment to Jaguar ($16M upon deal closing and $2M upon completion of post-closing conditions)Up to additional $20M in milestone and other future paymentsFuture Pak becomes exclusive U.S.... ► Artikel lesen |
| Jaguar Health, Inc.: Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication | Article discusses results demonstrating parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failureAssociated... ► Artikel lesen |
| Windtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech Space | Windtree is executing its corporate strategy to diversify its business with revenue and profit generating divisions CommLoan, Inc. is a tech company focused on transforming the way middle market loans... ► Artikel lesen |
| Grosvenor Invests in Wint to Strengthen Water Intelligence and Sustainability Across Global Real Estate | "Water risk and water waste are growing issues for the built environment, and Wint's technology will deliver clear value across our portfolio."BOSTON and LONDON, Dec. 3, 2025 /PRNewswire/... ► Artikel lesen |
| Windtree Therapeutics Announces It May Receive License Agreement Payments from Its Licensee for Renewed Acute Pulmonary Development by the Licensee | The Company has a global license agreement for the acute pulmonary that could pay up to $78.9 million in development, regulatory and commercial milestones plus low double digit royalties The licensed... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NETCAPITAL INC finden Sie auf Wallstreet Online.